MedMira获得加拿大卫生部批准其快速梅毒测试,尽管收入较低,但净损失减少。 MedMira gained Health Canada approval for its fast syphilis test and reduced net loss despite lower revenue.

MedMira Inc.获得加拿大卫生部批准,以进行加拿大批准最快的Reveal TP梅毒快速测试,并获得多波罗全面梅毒测试高级临床试验,并获得显示高精确度的数据支持。 MedMira Inc. received Health Canada approval for its Reveal® TP rapid syphilis test, the fastest approved in Canada, and advanced clinical trials for its Multiplo® Complete Syphilis test, supported by data showing high accuracy. 该公司正在开发一个AI综合诊断平台,并与分销伙伴合作扩大市场准入。 The company is developing an AI-integrated diagnostic platform and working with distribution partners to expand market access. 在财务方面,收入和毛利润略有下降,但业务费用大幅下降,净损失从130万美元减少到813 134美元。 Financially, revenue and gross profit declined slightly, but operating expenses dropped significantly, reducing the net loss to $813,134 from $1.3 million. 资产由于折旧而减少,而负债则因投资者预付款和债务的增加而增加。 Assets decreased due to depreciation, while liabilities rose from increased investor advances and debt.